Accumulation of MTA in MTAP-loss cancer cells sensitizes them to additional PMRT5 and MAT2A inhibition.12,28 This synthetic lethal relationship is now actively being exploited as a method of targeting MTAP-loss in early phase clinical trials enrolling advanced solid tumors. This evidence concerns the gene MTAP and cancer.